SK Bioscience Co (XKRX:302440) Net Change in Cash : ₩70,844 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

SK Bioscience Co's Net Change in Cash for the three months ended in Mar. 2025 was ₩-6,958 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was ₩70,844 Mil.

SK Bioscience Co Net Change in Cash Historical Data

The historical data trend for SK Bioscience Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Net Change in Cash Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

10,592.05

73,055.94

127,259.19

-98,261.81

185,675.87

SK Bioscience Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															107,874.24	56,673.28	220,705.62	-199,577.27	-6,957.55

SK Bioscience Co Net Change in Cash Calculation

SK Bioscience Co's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-128019.869	+	53563.803	+	252479.228	+	7652.705
	=	185,676

SK Bioscience Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 62745.242 + -75301.28 + -1837.111 + 7435.6

= -6,958

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩70,844 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SK Bioscience Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of SK Bioscience Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Net Change in Cash

Comparable Companies

XKRX:145020 XKRX:950160 XKRX:141080 XKRX:298380 XKRX:087010 XKRX:214450 XKRX:310210 XKRX:096530 XKRX:358570 XKRX:347850 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines